



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH

भारतीय आयुर्विज्ञान अनुसंधान परिषद
INDIAN COUNCIL OF MEDICAL RESEARCH

स्वास्थ्य अनुसंधान विभाग (स्वास्थ्य एवं परिवार कल्याण मंत्रालय)
वी रामलिंगस्वामी भवन, अन्सारी नगर, नई दिल्ली - 110029

DEPARTMENT OF HEALTH RESEARCH (MINISTRY OF HEALTH & FAMILY WELFARE)
V. RAMALINGASWAMI BHAWAN, ANSARI NAGAR, NEW DELHI-110029

No.E16/68/2022-Admn.

Dated:22/12/2022

To

The Directors/Directors-in-charge of
All Institutes/Centers of ICMR

Sir/Madam,

Please find enclosed the following letters which have been received from different Ministries/Departments for information and necessary action:

| S. No | Reference No. & Date | Name of Ministry | Subject |
|-------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | OM No.S.11011/11/2016 -CGHS(P) Dated: 22.11.2022 | Government of India, Ministry of Health & Family Welfare, Department of Health & Family Welfare | Revision of rates of subscription under Central Government Health Scheme due to revision of pay an allowances of Central Government employees and revision of pension/family pension on account of implementation of recommendations of the Seventh Central Pay Commission-reg. |
| 2. | OM No.F.4/1/2922-PPD(pt.) Dated:25.11.2022 | Government of India, Ministry of Finance, Department of Expenditure Procurement Policy Division | Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017. |
| 3. | DO.No.V-11011(13)/12/2022-CPCSEA-DADF Dated:29.11.2022 | Government of India, Ministry of Fisheries, Department of Animal Husbandry and Dairying | Provision for adequate funds for maintenance of animal house facility as per the guidelines of CPCSEA-reg. |

Yours faithfully

(Jagdish Rajesh)

Assistant Director General (Admin.)

Encl: As above

Copy to: 1. PS to DG/Sr. DDG(A)/Sr. FA

2. All Divisional Heads

3. DDG(A)/ ADG(A)/ ADG(F)

4. Dr. L.K. Sharma, Scientist "E"-soft copy of the same has been mailed at your email ID

(Sharma.lk@icmr.gov.in) for website upload



भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH

स्वास्थ्य अनुसंधान विभाग (स्वास्थ्य एवं परिवार कल्याण मंत्रालय)

वी रामलिंगस्वामी भवन, अन्सारी नगर, नई दिल्ली - 110029

DEPARTMENT OF HEALTH RESEARCH (MINISTRY OF HEALTH & FAMILY WELFARE)
V. RAMALINGASWAMI BHAWAN, ANSARI NAGAR, NEW DELHI-110029

क्रमांक.E16/68/2022-प्रशासन

दिनांक:22/12/2022

सेवा में,

निदेशक/प्रभारी निदेशक
परिषद के सभी संस्थान/केन्द्र

महोदय/महोदया,

विभिन्न मंत्रालयों/विभागों से प्राप्त निम्नलिखित पत्र, सूचना एवं आवश्यक कार्यवाही के लिए संलग्न है।

| S.No | Reference No. & Date | Name of Ministry | Subject |
|------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | OM No.S.11011/11/2016-CGHS(P) Dated: 22.11.2022 | Government of India, Ministry of Health & Family Welfare, Department of Health & Family Welfare | Revision of rates of subscription under Central Government Health Scheme due to revision of pay an allowances of Central Government employees and revision of pension/family pension on account of implementation of recommendations of the Seventh Central Pay Commission-reg. |
| 2. | OM No.F.4/1/2922-PPD(pt.) Dated:25.11.2022 | Government of India, Ministry of Finance, Department of Expenditure Procurement Policy Division | Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017. |
| 3. | DO.No.V-11011(13)/12/2022-CPCSEA-DADF Dated:29.11.2022 | Government of India, Ministry of Fisheries, Department of Animal Husbandry and Dairying | Provision for adequate funds for maintenance of animal house facility as per the guidelines of CPCSEA-reg. |

भवदीय,
22/12/22
जगदीश राजेश

जगदीश राजेश
सहायक महानिदेशक (प्रशासन)

अनुलग्नक:यथोक्त

प्रतिलिपि: 1. महानिदेशक/वरि.उपमहानिदेशक (प्रशा.)/वरि.वित्त सलाहकार के निजी सचिव

2. परिषद के सभी प्रभाग प्रमुख

3. उपमहानिदेशक (प्रशा.)/सहा. महानिदेशक (प्रशा.)/सहा. महानिदेशक (वित्त.)

4. डॉ.एल.के शर्मा, वैज्ञानिक ई: वैबसाइट पर अरपलोड करने के लिए ईमेल आईडी

(sharma.lk@icmr.gov.in) पर मेल कर दिया गया है।

142748

D.G. ICMR OFFICE
Diary No. 642063

Date 2/12/22

File No: S.11011/11/2016-CGHS(P)
Government of India
Ministry of Health & Family Welfare
Department of Health & Family Welfare
(EHS Section)

Nirman Bhawan, New Delhi
Dated the 22nd November, 2022

OFFICE MEMORANDUM

Subject: Revision of rates of subscription under Central Government Health Scheme due to revision of pay and allowances of Central Government employees and revision of pension/ family pension on account of implementation of recommendations of the Seventh Central Pay Commission-reg.

In continuation of this Ministry's OM of even number dated 28.10.2022 (copy enclosed) on the subject cited above, the undersigned is directed to issue clarifications, with regard to several clarification requests received in this Ministry. The clarifications on such issues raised may be seen as under:

| Sl. No. | Issues raised | Clarification |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| i. | Is this OM applicable to pensioners of autonomous bodies under CGHS too? | Autonomous Bodies/ Statutory Bodies are provided only OPD facilities, under CGHS, on cost to cost basis. IPD treatment costs are borne by the concerned ABs/SBs through their own resources. Therefore, it is for the concerned ABs/SBs to whom CGHS facilities have been extended, to take a decision in the matter. |
| ii. | Is this OM applicable to pensioners who have retired prior to October 2022? Out of these retirees, some have given life time contribution while others contribute on a yearly basis. | The OM dated 28.10.2022 has been issued with the approval of D/o Expenditure, M/o Finance, to rectify certain anomalies in the ward entitlement of beneficiaries post 7 th CPC, as fixed vide OM dated 09.01.2017. There is no change in the subscription rate as already fixed vide OM dated 09.01.2017. There is no linkage between CGHS subscription and ward entitlement. |
| iii. | Many pensioners who have retired on 31/10/2022 had applied for pensioners' card with contribution before 28/10/2022. What would be the status of their ward entitlement? | Therefore, all CGHS beneficiaries (Serving & Pensioners) who are eligible for upgradation of their ward entitlement, according to the revised basic pay slabs, as mentioned in OM dated 28.10.2022, may apply for fresh CGHS card. However, Medical claim cases for treatment taken by beneficiaries prior to 28.10.2022, will not be re-opened for the purpose of reimbursement with regard to revised ward entitlement(s). |

JS (GN)
JS (AM)
S-DOs (A)

RB
2/12/22

2. This issues with approval of Competent Authority.

Hemlata Singh

(Hemlata Singh)
Under Secretary to the Government of India
Tel No. 011-23061778

Encl. As above.

D. S. ...

To

1. All the Ministries/ Departments, Government of India.

D. No. 558 Admn.
07/11/2022

Mr. Sarma

Amr
JIR

Adm

642063/22

DDA (A)

B

6.12.22

Receipt No.
643838/12/12/22

28 NOV 2022
642063

2. Director (CGHS), Nirman Bhawan, New Delhi.
3. Addl.DDG(HQ), CGHS, MoHFW, Nirman Bhawan, New Delhi.
4. AD(HQ), CGHS, RK Puram, New Delhi.
5. All Addl. Directors/ Joint Directors of CGHS cities outside Delhi.
6. Additional Director (SZ)/(CZ)/(EZ)/(NZ)/(MSD), MCTC CGHS, New Delhi
7. JD(HQ), JD (Grievance)/JD (R&H), CGHS, Delhi
8. DDG(M), Dte.GHS, MoHFW, Nirman Bhawan, New Delh
9. Rajya Sabha/Lok Sabha Secretariat, New Delhi
10. Registrar, Supreme Court of India, New Delhi
11. U.P.S.C. Dholpur House, new Delhi
12. Office of the Comptroller & Auditor General of India, Bahadur Shah Zafar Marg, New Delhi
13. Director, Department of Pension & Pensioners Welfare, Lok Nayak Bhawan, Khan Market, New Delhi
14. PPS to Secretary (H&FW)/Secretary (HR), Ministry of Health & Family Welfare
15. PPS to DGHS/AS&DG(CGHS)/AS&FA/AS&MD), NHM/AS(H), MoHFW, New Delhi
16. MG-II Section, Dte.GHS, MoHFW, Nirman Bhawan, New Delhi.
17. Hospital Empanelment Cell, CGHS, MoHFW, Nirman Bhawan, New Delhi.
18. CGHS-I/II/III/IV, Dte.CGHS, MoHFW, Nirman Bhawan, New Delhi.
19. Estt.I/Estt.II/Estt.III/Estt.IV Section, MoHFW, Nirman Bhawan, New Delhi.

F. No. S.11011/11/2016-CGHS(P)/EHS
Government of India
Ministry of Health & Family Welfare
Department of Health & Family Welfare
(EHS Section)

Dated, the 28th October, 2022
Nirman Bhawan, New Delhi

OFFICE MEMORANDUM


Subject: Revision of rates of subscription under Central Government Health Scheme due to revision of pay and allowances of Central Government employees and revision of pension/ family pension on account of implementation of recommendations of the Seventh Central Pay Commission.

In partial modification to this Ministry's O.M. of even number dated 9th January, 2017, the undersigned is directed to say that entitlement of wards in private hospitals empanelled under CGHS as contained in Para 3(B) of the O.M. *ibid* stands revised as under with effect from the date of issue of this O.M. :-

| Sl. No. | Corresponding Basic Pay drawn by Officer in 7 th CPC per month | Ward Entitlement |
|---------|---------------------------------------------------------------------------|------------------|
| 1 | Upto Rs. 36,500 | General |
| 2 | Rs. 36,501 to Rs. 50,500 | Semi-Private |
| 3 | Above Rs. 50,500 | Private |

2. This issues with the concurrence of the Department of Expenditure vide their I.D. Note No. 18(1)/EV/2016 dated 11th May, 2022 read with I.D. Note dated 6th October, 2022.

3. Hindi Version follows.


(Guite Elsy Thang Biak Lun)

Under Secretary to Govt. of India

To

1. All the Ministries/Departments, Government of India.
2. Director, CGHS, Nirman Bhawan, New Delhi
3. Addl.DDG(HQ), CGHS, MoHFW, Nirman Bhawan, New Delhi
4. AD(HQ), CGHS, R.K. Puram, New Delhi
5. All Addl. Directors/Joint Directors of CGHS cities outside Delhi.
6. Additional Director (SZ)/(CZ)/(EZ)/(NZ)/(MSD), MCTC CGHS, New Delhi
7. JD(HQ), JD (Grievance)/JD (R&H), CGHS, Delhi
8. DDG(M), Dte.GHS, MoHFW, Nirman Bhawan, New Delhi
9. Rajya Sabha/ Lok Sabha Secretariat, New Delhi
10. Registrar, Supreme Court of India, New Delhi
11. U.P.S.C. Dholpur House, New Delhi
12. Office of the Comptroller & Auditor General of India, Bahadur Shah Zafar Marg, New Delhi
13. Director, Department of Pension & Pensioners Welfare, Lok Nayak Bhawan, Khan Market, New Delhi.
14. PPS to Secretary (H&FW)/ Secretary (HR), Ministry of Health & Family Welfare
15. PPS to DGHS/AS&DG(CGHS)/AS&FA/AS&MD, NHM/AS(H), MoHFW, New Delhi
16. MG-II Section, Dte.GHS, Nirman Bhawan, New Delhi
17. Hospital Empanelment Cell, CGHS, MoHFW, Nirman Bhawan, New Delhi
18. CGHS-I/II/III/IV, Dte.CGHS, MoHFW, Nirman Bhawan, New Delhi
19. Estt.I/Estt.II/Estt.III/Estt.IV Section, MoHFW, Nirman Bhawan, New Delhi.

| | |
|-------------|------------------------|
| Private | Rs. 50.00 |
| Sub-Private | Rs. 50.00 to Rs. 50.00 |
| General | Rs. 50.00 |
| Appointment | Rs. 50.00 per month |



ADMN-II ADMN <adm2355@gmail.com>

Fwd: Fwd: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017

1 message

R Lakshminarayanan <lakshminarayanan.r@icmr.gov.in>

Sun, Dec 4, 2022 at 9:11 AM

To: adm2355 <adm2355@gmail.com>

Cc: SAFAL CHETRI CHETRI <chetri.s@icmr.gov.in>, Jagdish Rajesh <rajeshj.hq@icmr.gov.in>, JOY Kumar Chakma <drjoyk@icmr.gov.in>, Sr DDG Admin <srddga.hq@icmr.gov.in>

Please circulate.

Thanks

Dr R Lakshminarayanan
Deputy Director General (A) &
Vigilance Officer
ICMR HQ, New Delhi.

----- Forwarded Message -----

From: Sr DDG Admin <srddga.hq@icmr.gov.in>

To: JOY Kumar Chakma <drjoyk@icmr.gov.in>, R Lakshminarayanan <lakshminarayanan.r@icmr.gov.in>

Sent: Sun, 04 Dec 2022 11:31:36 +0530 (IST)

Subject: Fwd: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017

From: "Office of Secretary DHR" <secy-dhr@gov.in>

To: "Anu Nagar" <anu.nagar1@gov.in>, "geetan" <geetan@nic.in>, "Sr DDG Admin" <srddga.hq@icmr.gov.in>, "Rajeev Roy" <rajeev.roy@gov.in>

Cc: "DG ICMR" <dg@icmr.org.in>

Sent: Friday, November 25, 2022 12:35:06 PM

Subject: Fwd: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017

From: "Usha Rani" <usha.rani64@gov.in>

To: "Manoj Ahuja" <Secy-agri@nic.in>, "Dr(Mr) Himanshu Pathak" <dg.icar@nic.in>, "Shri Rajesh Kumar Singh IAS" <secyahd@nic.in>, chairman@dae.gov.in, "RAJESH KOTECHA" <secy-ayush@nic.in>, "Office of Secretary CPC" <sec.cpc@nic.in>, "Ms S. Aparna" <secy-pharma@nic.in>, "Secy moca" <secy.moca@nic.in>, "Secretary Coal" <secy.moc@nic.in>, "Commerce Secretary Office" <csoffice@nic.in>, "Secy DPIIT" <secy-ppa@nic.in>, "K Rajaraman" <secy-dot@nic.in>, "ROHIT KUMAR SINGH" <secy-ca@nic.in>, "Ajay Kumar Bhalla" <hshsq@nic.in>, "Shri Sanjeev Chopra" <secy-food@nic.in>, "Secretary MCA" <secy.mca@nic.in>, "Govind Mohan" <secy-culture@nic.in>, "Shri Giridhar Aramane" <defsecy@nic.in>, "Secretary DP" <sdps@nic.in>, "Shri Vijoy Kumar Singh IAS" <secyesw@nic.in>, "Mr Lok Ranjan" <secydoner@nic.in>, "Ms. Vini Mahajan" <secydws@nic.in>, "Dr M Ravichandran" <secretary@moes.gov.in>, "Secretary MeitY" <secretary@meity.gov.in>, "Ms Leena Nandan" <secy-moef@nic.in>, "Dr. Ausaf Sayeed" <secycpv@mea.gov.in>, "Shri Ajay Seth" <secy-dea@nic.in>, "Secretary DFS" <secy-fs@nic.in>, "Shri Tarun Bajaj Secretary DOR" <rsecy@nic.in>, "Secretary MoFPI" <secy.mofpi@nic.in>, "Mr Rajesh Bhushan" <secyhfw@nic.in>, "Shri Kamran Rizvi" <shioff@nic.in>, "Shri Ali R. Rizvi" <secy-dpe@nic.in>, "Anuradha Prasad" <secy-iscs@nic.in>, "SECRETARY,OL" <secy-ol@nic.in>, "Manoj Joshi" <secyurban@nic.in>, "K. Sanjay Murthy" <secy.dhe@nic.in>, "Ms Anita Karwal" <secy.sel@nic.in>, "Apurva Chandra" <secy.inb@nic.in>, "Secretary DIPAM" <secydivest@nic.in>, "Shri Pankaj Kumar" <secy-mowr@nic.in>, "O/o Secy Labour Employment" <secy-labour@nic.in>, "Shri S.K.G Rahate" <secy-jus@gov.in>, "Bidyut Behari Swain" <secretary-msme@nic.in>, "Vivek Bharadwaj" <secy-mines@nic.in>, "Secretary, Minority Affairs" <secy-mma@nic.in>, "Bhupinder S Bhalla IAS" <secy-mnre@nic.in>, "Mr Sunil Kumar" <secy-mopr@nic.in>, "Gudey Srinivas" <secympa@nic.in>, "Shri V. Srinivas" <secy-arop@nic.in>, "Office

D.No. 555 Admin
5/12/2022

Receipt No. 642955/05/12/22

Mr. Sumit
Sumit
5/12/22

12/5/22, 10:46 AM

Gmail - Fwd: Fwd: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017

of Secretary, Personnel" <secy_mop@nic.in>, "Secy PNG" <sec.png@nic.in>, "Office of Secretary Ports Shipping and Waterways" <secyship@nic.in>, "Shri Alok Kumar" <secy-power@nic.in>, "SecretaryRlyBoard RailwayBoard" <secyrb@rb.railnet.gov.in>, "SECRETARY MORTH" <Secy-road@nic.in>, "Mr Ajay Tirkey" <secy-dolr@nic.in>, "NAGENDRA NATH SINHA" <secyrd@nic.in>, "SECRETARY DST" <dstsec@nic.in>, "Dr Rajesh S Gokhale" <secy.dbt@nic.in>, "Director General CSIR" <dgcsir@csir.res.in>, "Atul Kumar Tiwari" <secy-msde@nic.in>, "Sh Rajesh Aggarwal" <secretaryda-msje@nic.in>, chairman@isro.gov.in, "Dr(Mr) G P Samanta" <secretary@mospi.gov.in>, "Sanjay Singh" <secy-steel@nic.in>, "Rachna Shah" <secy-textiles@nic.in>, "Secretary Tourism" <sectour@nic.in>, "Lakshmi Naryain" <secy-tribal@nic.in>, "Mr Indevan Pandey" <secy.wcd@nic.in>, "Sujata Chaturvedi" <secy-sports@nic.in>, "Secretary Youth Affairs" <secy-ya@nic.in>, "Secretary Posts" <secretary-posts@indiapost.gov.in>, "Secretary DRDO" <secydrdo@gov.in>, "Jatindranath Swain" <secy-fisheries@gov.in>, "Anjali Bhawra" <secywel@nic.in>, "Office of Secretary DHR" <secy-dhr@gov.in>, "Secretary LD" <secyoffice-ld@gov.in>, "Gyanesh Kumar" <secy-coop@gov.in>, "Secretary Coordination" <secycoord@gov.in>, "ChairmanRailwayBoard RailwayBoard" <crb@rb.railnet.gov.in>, "Shri P. Daniel, Secretary, Central Vigilance Commission" <secy.cvc@nic.in>, "Rajiv Gauba" <cabinetsy@nic.in>
Cc: "Sanjay Aggarwal" <sanjay.aggarwal68@nic.in>, "KANWALPREET" <kanwal.irss@gov.in>, "Sudesh Kumar" <sudesh.kumar85@gov.in>

Sent: Friday, November 25, 2022 12:29:32 PM

Subject: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017

Madam/Sir,


Please find attached OM No. 4/1/2022-PPD(pt) dated 25.11.2022.

Regards,

Usha Rani
Under Secretary
Procurement Policy
DoE, MoF

[<https://amritmahotsav.nic.in/>]

[<https://amritmahotsav.nic.in/>]

 OM No 4 1 2022 PPD Pt dated 25 11 2022.pdf
3014K

No.F.4/1/2022-PPD(pt.)
Government of India
Ministry of Finance
Department of Expenditure
Procurement Policy Division

513, Lok Nayak Bhavan
Khan Market, New Delhi
Dated the 25th November, 2022

OFFICE MEMORANDUM

Subject: Relaxation on Global Tender Enquiry (GTE) under Rule 161(iv) of General Financial Rules (GFRs) 2017.

Attention is invited to this Department's OM No. F.12/17/2019-PPD dated 15.05.2020 and 28.05.2020 regarding amendment in Rule 161(iv) of General Financial Rules (GFRs) 2017 stipulating that no Global Tender Enquiry (GTE) shall be invited for tenders upto Rs.200.00 crore or such limit as may be prescribed by this Department from time to time, without prior approval from the competent authority i.e. Secretary (Coordination), Cabinet Secretariat.

2. In this context, in view of request of Ministry of Health & Family Welfare (MoH&FW), it has been decided that 90 (67+23) Durgs/Medicines listed at Annexure-A will be exempted from the instructions issued by this department vide OMs No. F.12/17/2019-PPD dated 15.05.2020 & 28.05.2020 regarding GTEs. This exemption will be valid for all the tenders issued for such drugs/medicines till 31.03.2023.

3. This issues with the approval of Finance Secretary.

Usha Rani
25/11/2022
(Usha Rani)

Under Secretary(Procurement Policy)

Tel.24621304

email: usha.rani64@gov.in

To,

All the Secretaries and Financial Advisors to Government of India.

Copy to:

Secretary (Coordination), Cabinet Secretariat, Rashtrapati Bhawan, New Delhi.
Email :secypg@nic.in.

List of 90 (67+23) drugs/medicines exempted from the instructions of Department of Expenditure (DoE) issued vide OMs No. F.12/17/2019-PPD dated 15.05.2020 & 28.05.2020 regarding Global Tender Enquiry.

LIST of 67 DRUGS

| S.no | Name of the Medicine and Strength |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | Abemaciclib 150mg Tablet. |
| 2 | AFLIBERCEPT 40 MG |
| 3 | Apidra Solostar |
| 4 | ATEZOLIZUMAB 840 MG/ 1.2MG |
| 5 | Avelumab injection: 200 mg/10 mL (20 mg/mL) solution in single-dose vial |
| 6 | BASILIXIMAB 20 MG |
| 7 | Biphasic Insulin Aspart Inj- |
| 8 | Brolucizumab solution for injection 120 mg/ml(vial + filter needle) |
| 9 | Ceritinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Ceritinib 150mg |
| 10 | CETUXIMAB 100 MG |
| 11 | CETUXIMAB 500 MG |
| 12 | Creon 10000 |
| 13 | DARATUMUMAB 100 MG 400mg |
| 14 | DEGLUDEC 100 I.U./ML INSULIN, PREFILLED PEN 3 ML. |
| 15 | Desflurane Anaesthetic Liquid (SUPRANE) |
| 16 | Detemir Insulin 100iu/ml 3ml Pen |
| 17 | DULAGLUTIDE 0.75 MG (BRAND- TRULICITY 0.75MG) 1.5 |
| 18 | Dulaglutide Inj- Each 0.5 ml to contain: 1.5 mg of Dulaglutide, Citric Acid Anhydrous [0.07mg], Mannitol [23.2 mg], Polysorbate 80 [0.10 mg], Trisodium Citrate Dehydrate [1.37 mg] Water for injection |
| 19 | DURVALUMAB 120 MG/ 500MG |

| | |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20 | Each Tab/Cap contain: Alpelisib 150mg |
| 21 | Each Tab/Cap contain: Olaparib 150mg |
| 22 | Emicizumab Inj- Each Vial Contains : Emicizumab 30mg For Sub Cut Injection (R-DNA Origin), Each Vial Contains : Emicizumab 60mg For Sub Cut Injection (R-DNA Origin) |
| 23 | FACTOR EIGHT BYPASSING ACTIVITY - Containing : Factor Eight Bypassing activity, Anti- Inhibitor-Coagulant Complex. 500 IU. |
| 24 | Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) -50mg, Sorbitol -20.5mg, L-Histidine - 0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg |
| 25 | GOSERELIN 10.8 MG SR INJ (BRAND: ZOLADEX) 3.6 |
| 26 | HUMAN COAGULATION FACTOR VII INJ - Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 1mg, Each vial to contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 2mg |

42
25/11/2022


| | |
|----|------------------------------------------------------------------------------------------------------------------------------|
| 27 | Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16, 18) Vaccine, Recombinant & 0.5ml |
| 28 | Idursulfase injection : 6 mg/3 mL (2 mg/mL) in single-use vial |
| 29 | Imiglucerase injection: 400 units of imiglucerase as a lyophilized powder in a single-dose vial. |
| 30 | INJ AVELUMAB 200 MG |
| 31 | INJ PANITUMUMAB 100 MG (BRAND:INJ. VECTIBIX) |
| 32 | INJ PEMBROLIZUMAB 100 MG, 420 |
| 33 | INJ PERTUZUMAB 420 MG (BRAND:PERJETA) |
| 34 | INJ. INSULIN ASPART 100IU/ML-3 ML PENFILL.ONE PEN AND 20 NEEDLES FREE WITH EVERY 20 CATRIDGES |
| 35 | Inj. Insulin Degludec 70% + Insulin Aspart 30% 100 IU/ml., 3 ml. Cartridge (RYZODEG PENFILL.) |
| 36 | Inj. Liraglutide 18 mg per pen, 1 needle free per pen |
| 37 | INJ. MEPOLIZUMAB POWDER FOR SOLUTION 100 MG |
| 38 | Inj. Secukinumab 150 mg(Scapho) |
| 39 | Inj. Thyrotropin alfa1.1 mg (THYROGEN) |
| 40 | Insulin Analogue of 50% Insulin Aspart + 50% longer acting analogue 100 iu/ml. |

UB
25/11/2022

| | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 41 | INSULIN GLULISINE INJECTION(MONOCOMPONENT INSULIN GLULISINE) 100IU./ML,3ML CARTRIDGE WITH ONE NEEDLE FREE OF COST PER CARTRIDGE AND ONE COMPATIBLE DEVICE FREE OF COST PER TWENTY CARTRIDGES. |
| 42 | Insulin Inj-Each Cartridge to contain: 25% Lispro And 75% LisproProtamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] & 3ml Cartridge Each Cartridge to contain: 50% Lispro And 50% LisproProtamine Suspension (100 IU/ml) [Monocomponent Insulin, Recombinant DNA Origin] & 3ml Cartridge |
| 43 | Intravitreal Dexamethasone Implant- Each inj to contain: Intravitreal Dexamethasone 0.7mg |
| 44 | Laronidase injection: 2.9 mg/5 mL (0.58 mg/mL) of laronidase in a single-dose vial |
| 45 | Levonorgestrel- Each Sterile Intrauterine System to contain: Levonorgestrel 52mg (Levonorgestrel 20 Microgram / 24 Hours Intra Uterine Delivery System) |
| 46 | LYNPARZA |
| 47 | Mepolizumab Inj- Each Vial to contain: Mepolizumab 100mg |

UR
25/07/2022

| | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 48 | <p>Methoxy Polyethylene Glycol Epoetin-Beta-</p> <p>Each PFS to contain: Methoxy Polyethylene Glycol Epoetin-Beta 100mcg, Methoxy Polyethylene Glycol Epoetin- Beta-</p> <p>Each PFS to contain: Methoxy Polyethylene Glycol Epoetin-Beta 50mcg, Methoxy Polyethylene Glycol Epoetin- Beta-</p> <p>Each PFS to contain: Methoxy Polyethylene Glycol Epoetin-Beta 75mcg</p> |
| 49 | <p>Midostaurin Tab/Cap- Each Tab/Cap</p> <p>Contains:Midostaurin 25mg</p> |
| 50 | <p>NIVOLUMAB 100 MG INJ (BRAND:OPDYTA), Each 4 ml Vial to contain: Nivolumab 40mg</p> |
| 51 | <p>Obinutuzumab Inj- Each Vial to contains: Obinutuzumab 1000 mg</p> |
| 52 | <p>PERITONEAL DIALYSIS FLUIDS 1.5% - Each 100ml to contain: Dextrose Anhydrous 1.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg & 5Ltr Bag, Peritoneal Dialysis Fluids 1.5%- Each 100ml to contain: Dextrose Anhydrous 1.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg & 2Ltr Bag, PERITONEAL DIALYSIS FLUIDS 2.5% - Each 100ml to contain: Dextrose Anhydrous 2.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg & 5Ltr Bag, Peritoneal Dialysis Fluids 2.5%- Each 100ml to contain: Dextrose Anhydrous 2.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg & 2Ltr Bag</p> |


 257 1/13/2022

| | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 53 | Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml) |
| 54 | RAMUCIRUMAB 100 mg&500 MG(BRAND- CYRAMZA) |
| 55 | Ryzodeg penfil |
| 56 | Secukinumab Inj- Each 1 ml to contain: Secukinumab 150mg, Sucrose 92.43mg, L- Histidine / L- Histidine Hcl Monohydrate 4.656 mg, Polysorbate 80 - 0.60mg. |
| 57 | Tab./ Cap. (Netupitant 300 mg. + Palanosetron 0.5 mg.) (AKYNZEO CAPS.) |
| 58 | TUOJEO SOLOSTAR 1.5ML PEN(INSULIN GLARGINE INJECTION 300IU/ML)THREE NEEDLES FREE WITH ONE PEN. |
| 59 | TUROCTOCOG ALFA 500 I.U. INJECTION |
| 60 | VERTEPORFIN 15 MG |
| 61 | Ceftazidim 2gm + Avibactam 500mg Inj. |
| 62 | Crizotinib Tab/Capsule (250 Mg) |
| 63 | Tab. Dacomitinib Monohydrate 30 mg.(Tab Dacoplice 30 Mg.) |
| 64 | Isavuconazole 100 mg caps. |
| 65 | Liraglutide 18 mg |
| 66 | Ceftaroline 600 mg/vial |
| 67 | Palbociclib 75 mg/100mg/125 mg |

UB
25T x/1/2022

LIST of 23 DRUGS

| S.no | Name of the medicine & Strength |
|------|--------------------------------------------------------------------------|
| 1 | AFATINIB 20 MG TAB 30 MG, 40MG |
| 2 | ALECENSA 150 MG |
| 3 | AXITINIB TAB/CAP 5 MG |
| 4 | CANAGLIFLOZIN+METFORMIN TAB/CAP- |
| 5 | ELTROMBOPAG TABLETS 25 MG, ELTROMBOPAG TABLETS 50 MG (REVOLADE 25/50 MG) |
| 6 | EMPAGLIFLOZIN 10 MG+LINAGLIPTIN 5 MG TAB/CAP |
| 7 | EMPAGLIFLOZIN 10 MG+ TAB (BRAND:JARDIANCE)25, |
| 8 | INVOKANA (CANAGLIFLOZIN 100 MG TABLETS) |
| 9 | LINAGLIPTIN 2.5 MG + METFORMIN 500 MG TAB/CAP |
| 10 | NILOTINIB 150 MG TAB (BRAND:TASIGNA)200MG |
| 11 | OSIMERTINIB 80 MG |
| 12 | RECOMBINANT ANTI HEMOPHILLIC FACTOR-VIII |
| 13 | RECOMBINANT ANTIHEMOPHILLIC FACTOR-VIII |
| 14 | RIBOCICLIB TABLET/CAPSULE 200 MG (BRAND KRYXANA) |
| 15 | RUXOLITINIB 15 MG, 5 MG, 20 MG TABLET (BRAND JAKAVI) |

UB
25/11/2022

| | |
|----|--------------------------------------------------------------------------------------------|
| 16 | SACUBITRIL 24 MG+VALSARTAN 26 MG TABLET, 49/51 MG, 97/103 MG (VYMADA 100 MG)VILDA |
| 17 | SAXAGLIPTIN TABLETS 2.5 MG, SAXAGLIPTIN TABLETS 5 MG |
| 18 | SAXAGLIPTIN & METFORMIN HYDROCHLORIDE EXTENDED RELEASE TABLETS |
| 19 | SUNITINIB MALATE TAB/CAP |
| 20 | TAB.BARICITINIB 2 MG, 4 MG |
| 21 | TAB.PAZOPANIB 400 MG. (TAB. VOTRIENT 400 MG.) |
| 22 | TAGRISSO 80 MG (OSIMERTINIB 80 MG) |
| 23 | VOTRIENT 200 MG 400 |

LB
257 x1/2022



डॉ. ओ. पी. चौधरी
अध्यक्ष (सीपीसीएसईए)
Dr. O. P. Chaudhary
Chairman (CPCSEA)

पशुओं पर परीक्षण के नियंत्रण एवं पर्यवेक्षण के प्रयोजनार्थ समिति (सीपीसीएसईए)
Committee for the Purpose of Control and Supervision of Experiments on Animals
(CPCSEA)

पशुपालन एवं डेयरी विभाग
मत्स्यपालन, पशुपालन एवं डेयरी मंत्रालय, भारत सरकार
Department of Animal Husbandry and Dairying,
Ministry of Fisheries, Animal Husbandry and Dairying, Government of India

D.G. ICMR OFFICE
Diary No. 642762
Date 2/12/22

D. O. No. V-11011(13)/12/2022-CPCSEA-DADF
29th November, 2022

Subject: Provision for adequate funds for maintenance of animal house facility as per the guidelines of CPCSEA – regarding

Dear

Dr Bahl,

As you are aware, the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) is constituted under Section 15 (1) of the Prevention of Cruelty to Animals Act, 1960, which is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pains or suffering before, during or after performance of experiments on them. The CPCSEA functions within the ambit of the Prevention of Cruelty to Animals Act 1960 and Rules for Breeding of and Experiments on Animal (Control and Supervision), 1998 as amended from time to time.

2. It has come to the notice of CPCSEA that many establishments under purview of Indian Council of Medical Research (ICMR) are not maintaining their animal houses as per the guidelines of CPCSEA due to unavailability of adequate funds. You are therefore requested to look into the matter and do the needful for provision of adequate funding for maintenance of animal house facilities so that research as well as animal welfare is not compromised.

With regards,

JS(AN) / C DDG(A)
SFA

RB.
21/12/22

Yours sincerely,

Dr. O.P. Chaudhary

Dr Rajiv Bahl,
Director General, Indian Council of Medical Research (ICMR),
Indian Council of Medical Research, Ansari Nagar New Delhi - 110029
Telephone : 011-26588204, Email : secy-dg@icmr.gov.in

Receipt No.
643840/12/12/2022

कक्ष संख्या 245, कृषि भवन, नई दिल्ली - 110001
Room No. 245, Krishi Bhawan, New Delhi - 110001

Tel No.: +91-11-23387804, Fax: +91-11-23386115,
E-mail: jspfdadf@gmail.com, jspf-dadf@nic.in

1 of 1 D. No. 559 Admn.,
07/11/22

Dr. Sumit
Shankar
21/12

DDG(A)

6.12.22

Please circulate

21/12/22

11/30/2022, 12:06 PM

Provision for adequate funds for maintenance - regarding.

From : CPCSEA DAHD <cpcsea-mef@gov.in>

Wed, Nov 30, 2022 11:53 AM

Subject : Provision for adequate funds for maintenance - regarding.

1 attachment

To : DG ICMR <secy-dg@icmr.gov.in>

Sir,

Please find attached letter regarding provision of adequate funds for maintenance of animal house facility as per the guidelines of CPCSEA.

--
**Office of the CPCSEA,
Department of Animal Husbandry and Dairying,
Ministry of Fisheries, Animal Husbandry and Dairying,
New Delhi.**



— Dr. Rajiv Bahl.pdf

222 KB